Table 3.
The baseline characteristics of the healthy control subjects and the enrolled IPF patients
| Control (n = 21) | IPF (n = 41) | |
|---|---|---|
| Sex, male, n (%) | 16 (76) | 32 (78) |
| Age, median (IQR) | 69 (66–73) | 72 (68–80) |
| Surgical lung biopsy undergo, n (%) | N.A. | 15 (36) |
| Baseline % predicted VC, median (IQR) | 109 (100–120) | 81 (67–93) |
| Emphysematous lesion detected by CT, n (%) a | N.A. | 4 (10) |
| Biomarker, median (IQR) | ||
| KL-6 | N.A. | 739 (557–1320) |
| SP-D | N.A. | 207 (142–303) |
| LDH | N.A. | 208 (183–247) |
| Smoking history | ||
| Yes, n (%) | 17 (80) | 34 (82) |
| Therapy, n (%) | N.A. | |
| No treatment | N.A. | 24 (58) |
| Pirfenidone | N.A. | 10 (24) |
| Prednisolone | N.A. | 8 (19) |
| Cyclosporine A | N.A. | 2 (4) |
The data are expressed as the median values (IQR) or n (%)
N.A. not acquired, VC vital capacity, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D
a Goddard LAA score is ≥1